Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor

Thalidomide-based Immunomodulatory Drugs (IMiDs(®)), including lenalidomide and pomalidomide, are effective therapeutics for multiple myeloma. These agents have been approved with, or are under clinical development with, other targeted therapies including proteasome inhibitors, αCD38 monoclonal anti...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:PLoS One
Hlavní autoři: North, Brian J., Almeciga-Pinto, Ingrid, Tamang, David, Yang, Min, Jones, Simon S., Quayle, Steven N.
Médium: Artigo
Jazyk:Inglês
Vydáno: Public Library of Science 2017
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5338861/
https://ncbi.nlm.nih.gov/pubmed/28264055
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0173507
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky